Kinase drug discovery approaches in chronic myeloproliferative disorders. - Wikidata - awgldk - TriplyDB

Kinase drug discovery approaches in chronic myeloproliferative disorders.

Kinase drug discovery approaches in chronic myeloproliferative disorders.

http://www.wikidata.org/entity/Q37472874

about

Experience with ruxolitinib in the treatment of polycythaemia vera.MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera.Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.Recent developments on JAK2 inhibitors: a patent review.Targeting miR-375 in gastric cancer.Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.miR-216a may inhibit pancreatic tumor growth by targeting JAK2.Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.JAK2 variations and functions in lung adenocarcinoma.

P2860

Q33605624-1D4A2329-632D-42DE-99C2-CDDE5345B2F9 Q34120830-430F3A61-9D40-424D-A734-58472FE91728 Q36266377-3F3678CC-CE87-4806-9809-D4C4A97E8D49 Q36333764-B83B09D8-7F9E-4F8F-AA64-CA78EEDCD7C0 Q36776428-33BD13DE-B214-455D-BD83-409BF3140CB8 Q37703253-A056C688-F6D5-44BC-A804-E54A923F8BEE Q37873944-821432CC-A2B0-4D7D-B646-CFBCF2044372 Q38715100-55F34096-FFF9-4FAF-8F6C-2EA0163A6B16 Q38856141-E77F117F-5E18-42D6-8CE1-1B7B92020429 Q39610375-DB5E69B3-9441-4BA7-97DA-076292BFC84A Q39827973-C6A8CAA8-8771-4258-AEA7-7D8C8DEC6976 Q42725814-F9FBA358-756B-458E-8274-B751213AF60A Q50929901-BA6C27B1-D304-478B-A056-42BEC2CE3943

P2860

Kinase drug discovery approaches in chronic myeloproliferative disorders.

http://www.wikidata.org/entity/Q37472874

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@en

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@nl

type

label

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@en

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@nl

prefLabel

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@en

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@nl

P1433

Q37472874-E2E7EB6A-638A-415A-BDC2-F99AC3379461

P1476

Q37472874-6E68A33D-7E5C-4848-A38A-2CB0EE0D07F7

P2093

Q37472874-0FE70E02-9195-4914-A837-98FA62BA9860

Q37472874-45CEFE0B-A1C2-497F-BA2E-FACD6A7692E7

Q37472874-8AE6AEDC-19D4-454A-81C0-F489566609BB

Q37472874-9A465CF7-F76D-4F59-9C6D-6FFA53BEFD62

P2860

Q37472874-091392CC-9997-4828-82DE-8026757C34AC

Q37472874-123C2FCE-CD89-4684-9E7D-96632EB49B32

Q37472874-13496144-0E30-4087-B6E5-36114ED99223

Q37472874-156B3A2E-F31B-4311-B9F7-0B8D441EB806

Q37472874-17F85B3C-10F5-4F53-8E3D-E36AD85429C1

Q37472874-18AA8D10-43BF-4FA8-85A0-FF78DFE7922A

Q37472874-210EFE85-19D0-4774-9F18-B6A915CD70BF

Q37472874-2352ADF9-994E-4441-8957-BC54BC13E375

Q37472874-2565FBB9-7D86-4327-9355-0A12DDBC67CD

Q37472874-27759B91-FE25-4C86-92E5-9B49A0241AAF

P2888

Q37472874-8D00A045-CEC3-4EE8-BE87-048B9525614C

P304

Q37472874-27BBBB88-0C82-4EEE-A499-A414D8CBE628

P31

Q37472874-4BE04589-4CBC-484B-B3FB-983C57357DC5

P356

Q37472874-C711E9CC-2A0F-4430-BF2A-DB34C5E898CE

P407

Q37472874-176466E5-7F86-4EC9-A5B8-F9409F1E4222

P433

Q37472874-B0D68A8C-6ED7-45B9-BFB4-F5D9BF6DDBF0

P478

Q37472874-F69DF40F-9DC0-4B34-BF24-403467C9B47D

P577

Q37472874-9ABAB5DA-489D-428E-8C30-F332DDF376BC

P5875

Q37472874-229AAF00-AAD6-4340-A777-333059855E20

P698

Q37472874-AB25239D-F9A3-4825-A09C-842B5336265D

P356

P1433

P1476

Kinase drug discovery approaches in chronic myeloproliferative disorders.

@en

P2093

A V Purandare

http://www.w3.org/2001/XMLSchema#string

C Kumar

http://www.w3.org/2001/XMLSchema#string

F Y Lee

http://www.w3.org/2001/XMLSchema#string

M V Lorenzi

http://www.w3.org/2001/XMLSchema#string

P2860

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

P2888

P304

2305-2313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2009.107

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24407188

http://www.w3.org/2001/XMLSchema#string

P698

19421140

http://www.w3.org/2001/XMLSchema#string